Pharmaceuticals
High-throughput screening workflows suffer from 90% failure rates because researchers cannot predict off-target toxicities early enough. Multi-head attention mechanisms forecast protein-ligand binding affinities directly from primary amino acid sequences to de-risk lead optimization.